United States - English - NLM (National Library of Medicine)

vedco, inc. - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - furosemide 12.5 mg - dogs - furosemide tablets are indicated for the treatment of edema (pulmonary congestion, ascites) associated with cardiac insufficiency and acute non-inflammatory tissue edema. in cases of edema involving cardiac insufficiency, the continued use of heart stimulants such as digitalis or its glycosides is indicated. the rationale for efficacious use of diuretic therapy is determined by the clinical pathology producing the edema. animal reproductive studies have shown that furosemide may cause fetal abnormality and the drug is contraindicated in pregnant animals. furosemide is contraindicated in anuria, furosemide hypersensitivity, hepatic coma, or during electrolytic imbalances. monitor serum electrolytes, bun and co2 frequently. monitor serum potassium levels and watch for signs of hypocalcemia. corticosteroids cause an additive potassium-depletion effect.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - furosemide 50 mg in 1 ml - dogs, cats & horses: salix® is an effective diuretic possessing a wide therapeutic range. pharmacologically it promotes the rapid removal of abnormally retained extracellular fluids. the rationale for the efficacious use of diuretic therapy is determined by the clinical pathology producing the edema. salix® is indicated for the treatment of edema, (pulmonary congestion, ascites) associated with cardiac insufficiency and acute noninflammatory tissue edema. the continued use of heart stimulants, such as digitalis or its glycosides is indicated in cases of edema involving cardiac insufficiency. cattle: salix® is indicated for the treatment of physiological parturient edema of the mammary gland and associated structures. salix® is a highly effective diuretic-saluretic which if given in excessive amounts may result in dehydration and electrolyte imbalance. therefore, the dosage and schedule may have to be adjusted to the patient's needs. the animal should be observed for early signs of electrolyte imbalance, a

United States - English - NLM (National Library of Medicine)

proficient rx lp - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

bionpharma inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

banner life sciences llc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.

United States - English - NLM (National Library of Medicine)

sigmapharm laboratories, llc - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules, usp, are a synthetic calcium regulator for oral administration. ergocalciferol is a white, colorless crystal, insoluble in water, soluble in organic solvents, and slightly soluble in vegetable oils. it is affected by air and by light. ergosterol or provitamin d2 is found in plants and yeast and has no antirachitic activity. there are more than 10 substances belonging to a group of steroid compounds, classified as having vitamin d or antirachitic activity. one usp unit of vitamin d2 is equivalent to one international unit (iu), and 1 mcg of vitamin d2 is equal to 40 iu. each capsule contains 1.25 mg (50,000 international units vitamin d) of ergocalciferol, usp, in an edible vegetable oil. ergocalciferol, also called vitamin d2, is 9, 10-secoergosta-5, 7, 10 (19), 22-tetraen-3-ol,(3β,5z,7e,22e)-; (c28h44o) with a molecular weight of 396.65, and has the following structural formula:

United States - English - NLM (National Library of Medicine)

rising pharamceuticals, inc - ergocalciferol (unii: vs041h42xc) (ergocalciferol - unii:vs041h42xc) - ergocalciferol 1.25 mg - ergocalciferol capsules are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin d resistant rickets, and familial hypophosphatemia. ergocalciferol capsules are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin d, and hypervitaminosis d.